100+ Active Companies working to develop 100+ Pipeline Therapies for Asthma Treatment Landscape | Major Companies - GSK, AstraZeneca, Teva Pharmaceuticals, and others

DelveInsight's, "Asthma Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Asthma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Asthma NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Key takeaways from Asthma Pipeline Insight Report

• DelveInsight's Asthma Pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Asthma.

• The leading Asthma Companies include Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others

• Promising Asthma Pipeline therapies include A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others.

• The Asthma companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The Asthma pipeline therapies under development are focused on novel approaches to treat/improve Asthma.

To explore more information on the latest breakthroughs in the Asthma Pipeline treatment landscape of the report, click here @ Asthma Pipeline Outlook- https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Asthma Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen.

Recent Breakthroughs of Asthma Treatment Landscape

• In October 2021, The board of directors of Mabpharm Limited announced that the new drug application (NDA) of CMAB007 (omalizumab), a core product of the Company, was accepted by the National Medical Products Administration of the People's Republic of China ("NMPA") for the treatment of allergic asthma, which is the first domestic allergic asthma therapeutic antibody new drug in China with NDA submitted. CMAB007 (omalizumab) is the second drug to be submitted for marketing application by the Company.

• In September 2021, Evelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria. This patent is a key addition to the Company's substantial and growing intellectual property (IP) portfolio for treatments targeting the small intestinal axis, SINTAX™.

• In November 2021, CSPC Pharmaceutical Group Limited (the "Company" announced that Shanghai JMT-BIO Technology Co., Ltd, a wholly-owned subsidiary of the Company, has entered into an agreement (the "Agreement") with Keymed Bioscience (Chengdu) Co., Ltd. in relation to the exclusive licensing and commercialization of the product CM326 (an anti-TSLP recombinant humanized monoclonal antibody, the "Product") in the treatment of moderate to severe asthma, chronic obstructive pulmonary disease (COPD) and other respiratory system diseases.

• In November 2021, Amgen and AstraZeneca agreed to include AMG 104 / AZD8630 in the existing collaboration agreement between the parties. AMG 104 / AZD8630 becomes part of the collaboration with the companies sharing both costs and income, with no inventor royalty.

For further information, refer to the detailed Asthma Unmet Needs, Asthma Market Drivers, and Asthma Market Barriers, click here for Asthma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Asthma Emerging Drugs Profile

PT-027: Avillion LLP
PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). It is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed in response to symptoms. It is an inhaled, fixed-dose combination of albuterol (also known as salbutamol), a SABA, and budesonide, a corticosteroid, and is being developed in a pMDI using AstraZeneca's Aerosphere delivery technology. Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the programme through to regulatory approval.

MM09-MG01: Inmunotek S.L.
It is a mite mixture (Dermatophagoides pteronyssinus and Dermatophagoides farinae) with a concentration of 30,000 AU / mL and grasses mixture (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca elatior, Lolium perenne and Dactylis glomerata) with a concentration of 30,000 AU / mL: Purified allergenic extract, adsorbed in aluminum hydroxide and polymerized with glutaraldehyde. It is currently being developed in Phase III stage of development.

FP 025: Foresee Pharmaceuticals
Foresee is developing a new generation, novel oral, highly selective and potent non-hydroxamate class of matrix metalloproteinase-12 (MMP-12) inhibitors for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and multiple other diseases by rational drug design. A lead compound, FP-025, has been investigated in Phase I human clinical trials and proved to show acceptable safety and tolerability, and stable pharmacokinetics in healthy subjects. A Phase II proof-of-concept study in allergic asthma patients is currently being conducted in the Netherlands.

GB001: Gossamer Bio
GB001, a DP2 antagonist, may inhibit recruitment and activation of inflammatory cells in patients with asthma, consequently reducing airway inflammation. DP2 is a G-protein-coupled receptor selectively expressed by Type 2 T lymphocytes (Th2), eosinophils (Eos), basophils and Type 2 innate lymphoid cells (ILC2s). DP2 binds to PGD2 and promotes recruitment and activation of eosinophils and basophils and stimulates Th2 cells and ILC2 cells to release Type 2 cytokines including IL-4, IL-5 and IL-13, leading to persistence of Type 2 inflammation.GB001 is a potent and highly selective oral DP2 antagonist being developed as a once daily oral add-on maintenance treatment for moderate to severe eosinophilic asthma. In preclinical studies, GB001 was shown to be an insurmountable antagonist with a prolonged effect.

EDP1867: Evelo Biosciences, Inc.
EDP1867 is a non-live pharmaceutical preparation of a single strain of Veillonella parvula, isolated from the ileum of a human donor. It is made non-live by γ-irradiation in the manufacturing process making it unable to colonize or persist in the gut, a central feature of SINTAX medicines. EDP1867 is currently in clinical development. It has the potential to treat a wide range of inflammatory and neuroinflammatory diseases.

TQC2731: Chia Tai Tianqing Pharmaceutical Group
TQC2731, belongs to the class of antiasthmatics. These anti-inflammatory drugs are the most effective and commonly used long-term control medications for asthma. They reduce swelling and tightening in your airways. An antiasthmatic and antiallergic agent also prevents mast cell release of histamine and formation of other mediators (leukotrienes) of anaphylaxis by inhibiting degranulation after contact with antigens. These helps prevent symptoms of asthma, allergic rhinitis, mastocytosis, and exercise-induced bronchospasm.TQC2731 is currently being investigated in Phase1 for the treatment of Asthma.

Asthma Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Asthma. The companies which have their Asthma drug candidates in the most advanced stage, i.e. phase III include, Avillion LLP.

Request a sample and discover the recent advances in Asthma Ongoing Clinical Trial Analysis and Medications, click here @ Asthma Treatment Landscape- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Asthma Pipeline Report

• Coverage- Global

• Asthma Companies- Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, EMS, AstraZeneca, Inmunotek, Pearl Therapeutics Inc., Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, EURRUS Biotech, T-Balance Therapeutics, Teva Pharmaceutical Industries, Theravance Biopharma, Akeso Biopharma, Aldeyra Therapeutics, Gossamer Bio, Trio Medicines, Janssen Research & Development, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, Genentech, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Knopp Biosciences, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, Chiesi Farmaceutici S.p.A., Aquilon Pharma, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, and others

• Asthma Pipeline therapies- A2BR inhibitors, LNR 125.38, LABP-73, CM326, RG6314, KN-002, TQC2731, SB010, ADX-629, GSK3511294, BGF MDI, PT027, and others

• Asthma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Asthma Market Drivers and Asthma Market Barriers, click here @ Asthma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Asthma Executive Summary
3. Asthma: Overview
4. Asthma Pipeline Therapeutics
5. Asthma Pipeline Therapeutic Assessment
6. Asthma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. PT-027: Avillion LLP
9. Mid Stage Products (Phase II/III)
10. PT001: Pearl Therapeutics (AstraZeneca)
11. Mid Stage Products (Phase II)
12. FP 025: Foresee Pharmaceuticals
13. Early Stage Products (Phase I/II)
14. AQ-001S: Aquilon Pharmaceuticals S.A
15. Early Stage Products (Phase I)
16. Itolizumab (EQ001): Equillium
17. Preclinical and Discovery Stage Products
18. KBP7026: KBP Biosciences
19. Inactive Products
20. Asthma Key Companies
21. Asthma Key Products
22. Asthma- Unmet Needs
23. Asthma- Market Drivers and Barriers
24. Asthma- Future Perspectives and Conclusion
25. Asthma Analyst Views
26. Asthma Key Companies
27. Appendix

Got Queries? Find out the related information on Asthma Mergers and acquisitions, Asthma Licensing Activities @ Asthma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

This release was published on openPR.